Program - Society of Toxicology

More documents

Recommendations

Info

50 th Anniversary Annual Meeting and ToxExpo Program Description (Continued) Wednesday Abstract # Abstract # #2491 2:45 EXPOSURE DURING ALLERGIC SENSITIZATION TO URBAN SUMMER AND WINTER SAN JOAQUIN VALLEY COMBINED FINE/ULTRAFINE CONCENTRATED AMBIENT PARTICLES IN A MOUSE MODEL OF ALLERGIC AIRWAY INFLAMMATION. C. Carosino 1,2 , L. E. Plummer 1,2 , M. J. Kleeman 3 and K. E. Pinkerton 2 . 1 Pharmacology and Toxicology, University of California Davis, Davis, CA, 2 Center For Health and the Environment, University of California Davis, Davis, CA and 3 Civil and Environmental Engineering, University of California Davis, Davis, CA. #2492 3:03 SECONDHAND TOBACCO SMOKE, ANTIOXIDANT ENZYMES, AND AIRWAY DEVELOPMENT IN MALE AND FEMALE MICE. L. S. Van Winkle, J. Chan, P. Edwards, V. Rosauro, K. Sutherland and A. Buckpitt. University of California Davis, Davis, CA. #2493 3:21 ATMOSPHERIC AEROSOLS FORMED FROM BIOGENIC AND ANTHROPOGENIC PRECURSOR REACTIONS AND COAL COMBUSTION EMISSIONS SHOW MILD VASCULAR TOXICITY COMPARED WITH MOTOR VEHICLE EXHAUST. J. McDonald 1 , M. Doyle-Eisele 1 , A. Lund 1 , M. Campen 3 , E. Knipping 2 and A. Rohr 2 . 1 Lovelace, Albuqueruque, NM, 2 Electric Power Research Institute, Palo Alto, CA and 3 University of New Mexico, Albuquerque, NM. #2494 3:39 UNIQUE ASSOCIATIONS OF PM2.5 – INDUCED CHANGES IN HEART RATE VARIABILITY IN SPONTANEOUSLY HYPERTENSIVE RATS WITH WIND DIRECTION AND SPECIFIC SOURCES IN STEUBENVILLE, OH. J. G. Wagner 1 , A. Kamal 2 , M. Morishita 2 , B. Mukherjee 2 , G. J. Keeler 2 , J. R. Harkema 1 and A. C. Rohr 3 . 1 Michigan State University, East Lansing, MI, 2 University Michigan, Ann Arbor, MI and 3 Electrical Power Research Institute, Palo Alto, CA. #2495 3:57 INHALATION OF ULTRAFINE PARTICULATE MATTER INDUCES INFLAMMATORY GENE EXPRESSION IN STRIATUM THROUGH NRF-2 AND NF-κB PATHWAYS IN RATS EXPOSED IN MEXICO CITY. R. Guerra-Garcia 1 , E. Vera-Aguilar 2 , G. Gookin 3 , M. Uribe-Ramirez 1 , A. Campbell 4 , J. Camacho 2 , M. Kleinman 3 and A. De Vizcaya-Ruiz 1 . 1 Department of Toxicology, Cinvestav, Mexico City, Mexico, 2 Department Pharmacology, Cinvestav, Mexico City, Mexico, 3 Division of Occupational and Environmental Medicine, Department of Medicine, University of Irvine, Irvine, CA and 4 Department of Pharmacological Sciences, Western University of Health Sciences, Pomona, CA. Wednesday Afternoon, March 9 1:30 PM to 4:15 PM Room 202B Platform Session: Nrf2 and Antioxidant Response Networks Chairperson(s): Curtis Klaassen, University of Kansas Medical Center, Kansas City, KS, and Joshua P. Gray, U.S. Coast Guard Academy, New London, CT. #2496 1:30 NRF2 IN TOXICOLOGY: FROM MONOFUNCTIONAL INDUCERS TO THE NEXT GENERATION OF THERAPY. C. D. Klaassen. Pharmacology, University Kansas Medical Center, Kansas City, KS. #2497 1:51 TRANSCRIPTIONAL REGULATION OF THE HUMAN FERRITIN GENE THROUGH AN ANTI-OXIDANT RESPONSIVE ELEMENT BY CORE HISTONE MODIFICATIONS. B. Huang, K. Iwasaki and Y. Tsuji. Environmental and Molecular Toxicology, North Carolina State University, Raleigh, NC. Sponsor: J. Ninomiya-Tsuji. #2498 2:12 ACTIVATION OF NRF2 BY INTRINSIC AND EXTRINSIC LIGANDS. A. Chia, R. Megherbi, I. Copple, N. R. Kitteringham, L. E. Randle, C. E. Goldring and K. Park. Molecular & Clinical Pharmacology, University of Liverpool, Liverpool, Merseyside, United Kingdom. Sponsor: D. Mendrick. #2499 2:33 KEAP1-KNOCKDOWN AND HEPATOCYTE- SPECIFIC SIRT1 DELETION CONFER RESISTANCE TO FASTING-INDUCED DOWN-REGULATION OF NRF2-TARGET GENE EXPRESSION. S. Kulkarni 1 , J. Xu 1 , W. Wei 1 , X. Li 2 , M. Yamamoto 3 and A. Slitt 1 . 1 Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI, 2 National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC and 3 Department of Medical Biochemistry, Tohoku University Graduate School of Medicine, Sendai, Japan. #2500 2:54 A BIOCHEMICAL AND PROTEOMIC ANALYSIS OF THE EFFECT OF NRF2 GENE DELETION ON ACUTE ACETAMINOPHEN- INDUCED HEPATOTOXICITY. C. E. Goldring, L. E. Randle, R. L. Sison, N. R. Kitteringham, D. Denk, R. E. Jenkins, J. Walsh, B. Lane, A. Kipar and K. Park. Molecular & Clinical Pharmacology, University of Liverpool, Liverpool, Merseyside, United Kingdom. Sponsor: D. Mendrick. #2501 3:15 PROFILING ENVIRONMENTAL CHEMICALS IN THE ANTIOXIDANT RESPONSE ELEMENT PATHWAY USING QUANTITATIVE HIGH-THROUGHPUT SCREENING (QHTS). S. J. Shukla 1 , R. Huang 1 , S. O. Simmons 2 , R. R. Tice 3 , K. L. Witt 3 and M. Xia 1 . 1 NIH Chemical Genomics Center, Rockville, MD, 2 U.S. EPA, Research Triangle Park, NC and 3 National Toxicology Program, Research Triangle Park, NC. #2502 3:35 NUCLEAR FACTOR E2-RELATED FACTOR 1 IS INVOLVED IN ARSENIC-INDUCED ANTIOXIDANT RESPONSE IN HUMAN KERATINOCYTES. R. Zhao 1 , Y. Hou 1 , P. Xue 1 , C. G. Woods 1 , J. Fu 1 , M. P. Waalkes 2 , M. E. Andersen 1 and J. Pi 1 . 1 The Hamner Institutes, Reaserach Triangle Park, NC and 2 NTP, NIEHS, NIH, Research Triangle Park, NC. 336 Education-Career Development Sessions Exhibitor Hosted Sessions Featured Sessions Historical Highlights Informational Sessions Platform Sessions
Society of Toxicology 2011 Program Description (Continued) Abstract # #2503 3:55 BENEFICIAL ROLE OF NRF2 IN REGULATING NADPH GENERATION AND CONSUMPTION. K. C. Wu, J. Y. Cui and C. D. Klaassen. Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, Kansas City, KS. Wednesday Afternoon, March 9 2:30 PM to 3:30 PM Room 201 Meet the Director: U.S. FDA Director Chairperson(s): Michael P. Holsapple, International Life Sciences Institute, Washington, D.C. Lecturer: Jesse Goodman, U.S. FDA, Silver Spring, MD. U.S. FDA has defined regulatory science as the science of developing new tools, standards and approaches to assess the safety, efficacy, quality and performance of U.S. FDA-regulated products (see Advancing Regulatory Science for Public Health, 2010, accessible at: www.fda.gov/ scienceresearch/specialtopics/regulatoryscience/ucm228202.htm). No area of science is more important to our ability to predict a product’s safety, or assess the potential significance of chemical substances in products, than toxicology. Well performed toxicology studies have undoubtedly protected consumers from many unsafe products and from contaminants that pose true threats to health. Yet most of the toxicology tools in use for regulatory assessment have as of yet been essentially unchanged by the molecular and cellular revolutions of the last 40 years. A wealth of innovation based on application of genomic, proteomic, metabolic, cell based and modeling tools is being applied, largely in the research community, to assessing the effects of novel and existing compounds. These tools, if and as they are validated for their predictive capabilities, offer the potential to revolutionize toxicology and its use in safety assessments, dramatically improving our ability to detect, understand and manage potential risks. Improvements should occur both in sensitivity and in specificity—the goal should be to detect true risks, but to not reject products that are safe due to false positive signals that may not be predictive of target effects in humans (or, for that matter, in other parts of the ecosystem). In addition, there are compelling reasons to limit animal testing where other methods may either replace or improve prediction. In recognition of this potential, U.S. FDA has made “Transforming Toxicology” one of its broad strategic priorities in its Advancing Regulatory Science Initiative. U.S. FDA is including support for new approaches to toxicology in its joint NIH/FDA regulatory science grants, as well as in efforts in both its product centers and at the National Center for Toxicological Research. Enhancing toxicology studies for nanoparticles would receive enhanced support at U.S. FDA, and through collaborative studies, under the President’s 2011 budget proposal currently before Congress, which includes the first dedicated budget support line for regulatory science at U.S. FDA. The Office of the Chief Scientist recently formed a new U.S. FDA-wide Chemical and Environmental Science Council (CESC) to serve as a focus for more proactively managing the growing U.S. FDA portfolio of crosscutting chemical and toxicology issues, and to enhance scientific and policy communication, collaboration and training across U.S. FDA and with external partners. U.S. FDA has been increasingly engaged with colleagues in diverse agencies such as NIEHS (including through the NTP), U.S. EPA (including through the Tox-21 initiative and multiple specific issues), CDC and CPSC, among others. Such collaboration has, for example, been critical in the scientific response to potential health threats from the Gulf Oil Spill. Through these and other efforts, U.S. FDA has raised the profile of toxicology within the Agency and signaled its support for collaboration to advance the science needed to inform the best possible decisions. Abstract # Wednesday Afternoon, March 9 3:45 PM to 4:45 PM Room 201 Meet the Director: U.S. EPA Director Chairperson(s): Michael P. Holsapple, International Life Sciences Institute, Washington, D.C. Lecturer: Paul Anastas, U.S. EPA, Washington, D.C. (invited). Paul Anastas, Ph.D. is the Assistant Administrator for EPA’s Office of Research and Development (ORD) and the Science Advisor to the Agency. Known widely as the “Father of Green Chemistry” for his groundbreaking research on the design, manufacture, and use of minimally-toxic, environmentally-friendly chemicals, Dr. Anastas has an extensive record of leadership in government, academia, and the private sector. Dr. Anastas will participate in the Annual Meeting as guest lecturer in the Meeting the Director series of lectures, as well as serve as a panelist in a Workshop session entitled “Safer Products for a Sustainable World: Linking Chemical Design and Toxicology”, which will take place on Tuesday, March 8 from 9:00 AM to 11:45 AM. Wednesday Afternoon, March 9 4:30 PM to 5:50 PM Room 144 Roundtable Session: Assessment of Nanoparticle Exposure in Occupational Settings and in Inhalation Toxicology Studies: Is There a Best Dosemetric to Use? Chairperson(s): Günter Oberdörster, University of Rochester, Rochester, NY, and David Warheit, DuPont Haskell Global Centers, Newark, DE. Sponsor: Nanotoxicology Specialty Section Endorsed by: Inhalation and Respiratory Specialty Section Occupational and Public Health Specialty Section Regulatory and Safety Evaluation Specialty Section Nanotechnology involves the design and manipulation of materials at the nanoscale size range. The capacity for assessing hazards or quantifying exposures to engineered nanomaterials for workers or consumers is limited, and may require new or different methodologies to provide information for effective risk assessment and risk management. Exposure assessments are important components for determining health risks. However, currently used methodologies are inadequate for quantifying nanoparticulate exposures, because most of the occupational exposure data is represented in the gravimetric form of mass/volume of sampled air. Our goal is to address this controversial issue with a focus on practicability of measurements under workplace conditions. Therefore it is important to discuss the proposed change in dose metrics for inhalation toxicity studies with engineered aerosolized amorphous silica nanoparticles. Accordingly, rats were exposed to freshly generated nanoparticles at two different particle size ranges. The particle aerosols were characterized by particle numbers using SMPS technology. Our panel of experts will address the merits of using surface area metrics based on measurements of particle numbers and material-specific density for quantifying particle exposures and their use for risk assessment. Our panel will present real-time instrumentation for measuring airborne particle surface area and morphology of nanoparticle agglomerates—two of the important metrics for toxicity evaluation. In addition, recent exposure assessments in manufacturing facilities involving silicon nanoparticles and carbon nanotubes will be presented. It is also important to note the effect of agglomerate structure size on the bioactivity of nanoparticles and present current methods used to disperse nanoparticles for in vitro and in vivo testing which we will address. Finally, we will discuss methods to convert in vivo lung burdens to appropriate in vitro test concentrations of nanoparticles for hazard screening. Wednesday Poster Sessions Regional Interest Session Roundtable Sessions Symposium Sessions Thematic Sessions Workshop Sessions 337
Page 1 and 2:
50 th Anniversary Annual Meeting &
Page 3 and 4:
Scientific Program Overview A page
Page 5 and 6:
9:00 AM-12:30 PM POSTER SESSionS
Page 7 and 8:
March 6-10, 2011 Walter E. Washingt
Page 9 and 10:
Celebration Activities Historical H
Page 11 and 12:
of the Society Regional Chapter Yea
Page 13 and 14:
SOT Presidents 1961-2011 1966 1967
Page 15 and 16:
The SOT Council Thanks and Recogniz
Page 17 and 18:
of the Past 50 Years 2003 Michael D
Page 19 and 20:
Thank You to the following individu
Page 21 and 22:
SOT Celebration Event Floor Plan Ba
Page 23 and 24:
50 th Anniversary Annual Meeting an
Page 25 and 26:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 27 and 28:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 29 and 30:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 31 and 32:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 33 and 34:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 35 and 36:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 37 and 38:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 39 and 40:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 41 and 42:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 43 and 44:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 45 and 46:
Toxicological Sciences The Official
Page 47 and 48:
Society of Toxicology 2011 Walter E
Page 49 and 50:
Society of Toxicology 2011 Washingt
Page 51 and 52:
Society of Toxicology 2011 Map of W
Page 53 and 54:
2011 SOT 50 th Anniversary Featured
Page 55 and 56:
Society of Toxicology 2011 Washingt
Page 57 and 58:
Society of Toxicology 2011 ToxExpo
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Society of Toxicology 2011 Exhibito
Page 65 and 66:
Creating a Safer and Healthier Worl
Page 67 and 68:
Society of Toxicology 2011 General
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
SOT Job Bank YOUR RECRUITMENT AND E
Page 83 and 84:
Society of Toxicology 2011 Career R
Page 85 and 86:
Society of Toxicology 2011 SOT 2011
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Society of Toxicology 2011 2011 Awa
Page 95 and 96:
Endowment Awardees for SOT’s 50 t
Page 97 and 98:
Society of Toxicology 2011 SOT Endo
Page 99 and 100:
Society of Toxicology 2011 Recognit
Page 101 and 102:
Society of Toxicology 2011 Recognit
Page 103 and 104:
Society of Toxicology 2011 RC, SIG,
Page 105 and 106:
Society of Toxicology 2011 Student
Page 107 and 108:
Society of Toxicology 2011 Outreach
Page 109 and 110:
Society of Toxicology 2011 Satellit
Page 111 and 112:
Society of Toxicology 2011 Continui
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Society of Toxicology 2011 Scientif
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Society of Toxicology 2011 Poster S
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Society of Toxicology 2011 Program
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
Page 239 and 240:
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
Page 247 and 248:
Page 249 and 250:
Page 251 and 252:
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Page 265 and 266:
Page 267 and 268:
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
Page 307 and 308: Society of Toxicology 2011 Program
Page 357: Society of Toxicology 2011 Program
Page 381 and 382: Society of Toxicology 2011 Author I
Page 409 and 410:
Society of Toxicology 2011 Abstract
Page 411 and 412:
Page 413 and 414:
Page 415 and 416:
Page 417 and 418:
Page 419 and 420:
Page 421 and 422:
Page 423 and 424:
Page 425 and 426:
Society of Toxicology 2011 2010-201
Page 427 and 428:
Society of Toxicology 2011 Elected
Page 429 and 430:
Society of Toxicology 2011 Elected
Page 431 and 432:
Society of Toxicology 2011 Regional
Page 433 and 434:
Society of Toxicology 2011 Specialt
Page 435 and 436:
Society of Toxicology 2011 Specialt
Page 437 and 438:
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Page 439 and 440:
Society of Toxicology 2011 Endowmen
Page 441 and 442:
Page 443 and 444:
Page 445 and 446:
Page 447 and 448:
Society of Toxicology 2011 SOT Affi
Page 449 and 450:
Society of Toxicology 2011 Notes up
Page 451 and 452:
Society of Toxicology 2011 Notes up
Page 453 and 454:
Society of Toxicology 2011 Headquar
Page 455 and 456:
QUICK REFERENCE Visit www.mwata.com
show all

Program - Society of Toxicology

Create successful ePaper yourself

Delete template?

Save as template?